Futura Medical (FUM) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.940x

Based on the latest financial reports, Futura Medical (FUM) has a cash flow conversion efficiency ratio of -0.940x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.64 Million ≈ $-320.73 USD) by net assets (GBX2.81 Million ≈ $341.31 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Futura Medical to measure how much of total assets are equity-financed.

Futura Medical - Cash Flow Conversion Efficiency Trend (2001–2025)

This chart illustrates how Futura Medical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Futura Medical (FUM) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Futura Medical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Futura Medical ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Catenai PLC
LSE:CTAI
-0.188x
Gaming Technologies Inc. Common Stock
NASDAQ:GMGT
0.110x
Alina Holdings PLC
LSE:ALNA
-0.041x
Sonder Holdings Inc
NASDAQ:SOND
0.040x
Blue Star Capital plc
LSE:BLU
-0.049x
Botswana Diamonds plc
LSE:BOD
-0.001x
Physiomics Plc
LSE:PYC
-0.514x
Bollinger Innovations, Inc.
NASDAQ:BINI
0.194x

Annual Cash Flow Conversion Efficiency for Futura Medical (2001–2025)

The table below shows the annual cash flow conversion efficiency of Futura Medical from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see FUM market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 GBX2.81 Million
≈ $341.31
GBX-5.58 Million
≈ $-678.54
-1.988x -4164.32%
2024-12-31 GBX8.96 Million
≈ $1.09K
GBX438.41K
≈ $53.34
0.049x -53.02%
2023-12-31 GBX5.48 Million
≈ $666.37
GBX570.25K
≈ $69.38
0.104x +108.51%
2022-12-31 GBX4.72 Million
≈ $574.23
GBX-5.78 Million
≈ $-702.69
-1.224x -207.24%
2021-12-31 GBX9.72 Million
≈ $1.18K
GBX-3.87 Million
≈ $-471.26
-0.398x +92.52%
2020-12-31 GBX853.54K
≈ $103.85
GBX-4.54 Million
≈ $-552.79
-5.323x +95.71%
2019-12-31 GBX53.65K
≈ $6.53
GBX-6.66 Million
≈ $-809.87
-124.063x -23226.94%
2018-12-31 GBX8.85 Million
≈ $1.08K
GBX-4.71 Million
≈ $-572.83
-0.532x -16.00%
2017-12-31 GBX9.11 Million
≈ $1.11K
GBX-4.17 Million
≈ $-507.95
-0.458x -74.94%
2016-12-31 GBX12.58 Million
≈ $1.53K
GBX-3.30 Million
≈ $-401.27
-0.262x +76.61%
2015-12-31 GBX4.79 Million
≈ $582.35
GBX-5.36 Million
≈ $-652.63
-1.121x -255.27%
2014-12-31 GBX9.72 Million
≈ $1.18K
GBX-3.07 Million
≈ $-373.13
-0.315x +84.53%
2013-12-31 GBX987.77K
≈ $120.18
GBX-2.01 Million
≈ $-245.04
-2.039x -201.85%
2012-12-31 GBX2.87 Million
≈ $349.59
GBX-1.94 Million
≈ $-236.14
-0.675x -1.47%
2011-12-31 GBX2.76 Million
≈ $335.57
GBX-1.84 Million
≈ $-223.39
-0.666x +42.71%
2010-12-31 GBX901.00K
≈ $109.63
GBX-1.05 Million
≈ $-127.39
-1.162x -63.37%
2009-12-31 GBX1.85 Million
≈ $225.46
GBX-1.32 Million
≈ $-160.36
-0.711x +68.03%
2008-12-31 GBX886.00K
≈ $107.80
GBX-1.97 Million
≈ $-239.81
-2.225x -170.33%
2007-12-31 GBX2.77 Million
≈ $337.39
GBX-2.28 Million
≈ $-277.65
-0.823x -75.43%
2006-12-31 GBX3.95 Million
≈ $480.36
GBX-1.85 Million
≈ $-225.33
-0.469x +56.29%
2005-12-31 GBX1.98 Million
≈ $240.91
GBX-2.12 Million
≈ $-258.55
-1.073x -177.22%
2004-12-31 GBX3.75 Million
≈ $456.02
GBX-1.45 Million
≈ $-176.54
-0.387x +31.27%
2003-12-31 GBX2.41 Million
≈ $293.11
GBX-1.36 Million
≈ $-165.11
-0.563x +19.43%
2003-01-31 GBX1.52 Million
≈ $184.82
GBX-1.06 Million
≈ $-129.21
-0.699x -8.85%
2002-01-31 GBX2.00 Million
≈ $243.22
GBX-1.28 Million
≈ $-156.23
-0.642x -159.76%
2001-01-31 GBX-294.00K
≈ $-35.77
GBX-316.00K
≈ $-38.45
1.075x --

About Futura Medical

LSE:FUM UK Biotechnology
Market Cap
$26.81K
GBX220.32 Million GBX
Market Cap Rank
#31573 Global
#1245 in UK
Share Price
GBX0.38
Change (1 day)
+5.57%
52-Week Range
GBX0.31 - GBX11.53
All Time High
GBX84.52
About

Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Fut… Read more